FindTrial
Sign In

VX-147

DRUG4 trials

Sponsors

Vertex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated

Conditions

APOL1-mediated Proteinuric Kidney Disease (AMKD)Focal Segmental Glomerulosclerosis (FSGS)Glomerulosclerosis, Focal SegmentalProteinuric Kidney Disease

Phase 1

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
CompletedNCT05955872
Vertex Pharmaceuticals IncorporatedFocal Segmental Glomerulosclerosis (FSGS)
Start: 2023-07-19End: 2023-09-02Updated: 2023-09-13

Phase 2

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
CompletedNCT04340362
Vertex Pharmaceuticals IncorporatedGlomerulosclerosis, Focal Segmental
Start: 2020-06-08End: 2021-12-09Updated: 2025-09-24
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
RecruitingNCT05312879
Vertex Pharmaceuticals IncorporatedProteinuric Kidney Disease
Start: 2022-03-30End: 2030-05-07Target: 466Updated: 2026-09-09
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
RecruitingCTIS2024-515633-15-00
Vertex Pharmaceuticals Inc.APOL1-mediated Proteinuric Kidney Disease (AMKD)
Start: 2022-10-25Target: 33Updated: 2025-10-07

Related Papers

APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape.
2026-09-08
APOL1 Kidney Disease
Clinical Journal of the American Society of Nephrology2023-07-172 citations
Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> Variants
New England Journal of Medicine2023-03-15174 citations
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design.
2021-07-2330 citations